多西他赛联合希罗达治疗蒽环类失败复发转移性乳腺癌的疗效评价  

Clinical study of docetaxel and capecitabine(xeloda)combination in the treatment of patients with metastatic breast cancer and previously treaded with anthracyslines

作　　者：杨亮[1] 李涌涛[1] 艾斯卡[1] 张明帅[1] 

机构地区：[1]新疆医科大学附属肿瘤医院外二科,新疆乌鲁木齐830011

出　　处：《中国癌症杂志》2010年第5期390-392,共3页China Oncology

摘　　要：背景与目的:随着蒽环类药物在乳腺癌治疗中的广泛应用,对蒽环类耐药患者日渐增多,如何治疗蒽环类耐药的复发转移性乳腺癌已成为临床难题。本研究初步探讨了多西他赛联合希罗达治疗蒽环类药物治疗失败的复发转移性乳腺癌的疗效和安全性。方法:回顾性分析64例蒽环类药物治疗失败的复发转移性乳腺癌患者接受多西他赛联合希罗达方案的治疗情况。其中多西他赛75mg/m2,静脉滴注第1天;希罗达1250mg/m2,口服,每日2次,第1～14天,每21d为1个周期。每2个周期评价疗效同时记录不良事件。结果:对64例患者评价疗效,完全缓解(CR)6例,部分缓解(PR)33例,有效率(CR+PR)60.9%(39/64)。64例患者可评价不良反应,无严重不良事件导致死亡的患者,主要的不良反应为乏力、骨髓抑制、胃肠道反应和黏膜炎等,其中粒细胞减少Ⅲ～Ⅳ度为45.8%。结论:多西他赛联合希罗达是治疗蒽环类失败复发转移性乳腺癌的有效方案,其不良反应能够耐受。Background and purpose：With widely use of anthracyclines,patients are easily failed to respond to anthracyclines baseal regimens chemotherapy.Docetaxel and capecitabine（xeloda）are usually considered as the most active agents in breast cancer and are often used as adjuvant chemotherapy.In this study,we evaluated the efficacy and toxicity of docetaxel and xeloda combination regimen in the treatment of patients with metastatic breast cancer and previously treated with anthracyslines.Methods：64 patients who previously failed to respond to adriamycin based chemotherapy received docetaxel and xeloda combination regimen,docetaxel 75 mg/m2 ivgtt,day 1;xeloda 1 250 mg/m2,twice daily,day 1-14.The regimen was repeated every 21 days and the clinical response was recorded after 2 cycles.The effective patients received at least four cycles.Results：In 64 patients,the overall response rate was 60.9%,with 6 patieuts CR and 33 patients PR.The most frequent treatment-related adverse events were leukopenia, fatigue,nausea,vomiting and hand-foot syndrome.The main reactions were myelosuppression,III-IVas 45.8%. Conclusion：Good clinical efficacy were achieved in the therapy of metastatic breast cancer with docetaxel and xeloda combination regimen and toxic reactions are tolerable.

关 键 词：多西他赛 卡培他滨 乳腺癌 化疗疗法 

分 类 号：R730.53[医药卫生—肿瘤] R737.9[医药卫生—临床医学]